NO20031270L - Imidazolderivater som Raf-kinaseinhibitorer - Google Patents

Imidazolderivater som Raf-kinaseinhibitorer

Info

Publication number
NO20031270L
NO20031270L NO20031270A NO20031270A NO20031270L NO 20031270 L NO20031270 L NO 20031270L NO 20031270 A NO20031270 A NO 20031270A NO 20031270 A NO20031270 A NO 20031270A NO 20031270 L NO20031270 L NO 20031270L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
raf kinase
imidazole derivatives
migraine
pain
Prior art date
Application number
NO20031270A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031270D0 (no
Inventor
David Kenneth Dean
Andrew Kenneth Takle
David Matthew Wilson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0023193A external-priority patent/GB0023193D0/en
Priority claimed from GB0023197A external-priority patent/GB0023197D0/en
Priority claimed from GB0023196A external-priority patent/GB0023196D0/en
Priority claimed from GB0023208A external-priority patent/GB0023208D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20031270D0 publication Critical patent/NO20031270D0/no
Publication of NO20031270L publication Critical patent/NO20031270L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20031270A 2000-09-21 2003-03-19 Imidazolderivater som Raf-kinaseinhibitorer NO20031270L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0023193A GB0023193D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023197A GB0023197D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023196A GB0023196D0 (en) 2000-09-21 2000-09-21 Compouds
GB0023208A GB0023208D0 (en) 2000-09-21 2000-09-21 Compounds
PCT/GB2001/004195 WO2002024680A1 (en) 2000-09-21 2001-09-19 Imidazole derivatives as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20031270D0 NO20031270D0 (no) 2003-03-19
NO20031270L true NO20031270L (no) 2003-05-19

Family

ID=27447885

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031270A NO20031270L (no) 2000-09-21 2003-03-19 Imidazolderivater som Raf-kinaseinhibitorer

Country Status (21)

Country Link
US (2) US7199137B2 (pl)
EP (1) EP1318992B1 (pl)
JP (1) JP2004509882A (pl)
KR (1) KR20030030027A (pl)
CN (1) CN1471523A (pl)
AT (1) ATE300529T1 (pl)
AU (1) AU2001287901A1 (pl)
BR (1) BR0114023A (pl)
CA (1) CA2423154A1 (pl)
CY (1) CY1105251T1 (pl)
CZ (1) CZ2003793A3 (pl)
DE (1) DE60112312T2 (pl)
DK (1) DK1318992T3 (pl)
ES (1) ES2242767T3 (pl)
HU (1) HUP0301181A2 (pl)
IL (1) IL154949A0 (pl)
MX (1) MXPA03002449A (pl)
NO (1) NO20031270L (pl)
PL (1) PL361397A1 (pl)
PT (1) PT1318992E (pl)
WO (1) WO2002024680A1 (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60015594T2 (de) 1999-11-22 2005-10-27 Smithkline Beecham P.L.C., Brentford Imidazolderivate und deren verwendung als raf kinase inhibitoren
US7235658B2 (en) * 2000-03-06 2007-06-26 Smithkline Beecham P.L.C. Imidazol derivatives as Raf kinase inhibitors
US20040053943A1 (en) * 2000-11-20 2004-03-18 Adams Jerry L. Novel compounds
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US7446106B2 (en) 2001-09-05 2008-11-04 Smithkline Beecham Plc Pyridylfurans and pyrroles as Raf kinase inhibitors
WO2003022837A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Heterocycle-carboxamide derivatives as raf kinase inhibitors
GB0121490D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1492568A1 (en) * 2002-04-08 2005-01-05 SmithKline Beecham Corporation Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor
CA2495179A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
AU2003268064A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
NZ538225A (en) 2002-08-09 2008-05-30 Astrazeneca Ab "1,2,4"Oxadiazoles as modulators of metabotropic glutamate receptor-5
ES2497116T3 (es) 2002-08-19 2014-09-22 Lorus Therapeutics Inc. Imidazoles 2,4,5-trisustituidos y su uso como agentes antimicrobianos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
US20050250837A1 (en) * 2002-10-18 2005-11-10 D Mello Santosh R Use of C-Raf inhibitors for the treatment of neurodegenerative diseases
CN1784602A (zh) * 2003-04-14 2006-06-07 诺瓦提斯公司 用于治疗增生疾病和监视增生疾病治疗效果的方法
CA2540518A1 (en) * 2003-10-02 2005-04-07 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CA2611032C (en) 2005-05-25 2012-01-17 Genesense Technologies Inc. 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
CN103233063A (zh) * 2006-11-08 2013-08-07 密歇根大学董事会 前列腺癌标志物spink1及其应用
JP5693850B2 (ja) 2007-02-06 2015-04-01 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンおよびオキサビシクロヘプテン、それらの製造および使用
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
US8344135B2 (en) 2007-08-29 2013-01-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8143445B2 (en) * 2007-10-01 2012-03-27 Lixte Biotechnology, Inc. HDAC inhibitors
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
AU2009277086B2 (en) 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
JP5579619B2 (ja) 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP5800817B2 (ja) * 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US20130040983A1 (en) * 2010-01-08 2013-02-14 Jean-Michel Vernier Raf kinase inhibitors
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
WO2013022766A1 (en) * 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2014047330A1 (en) * 2012-09-19 2014-03-27 Jean-Michel Vernier Novel raf kinase inhibitors
WO2014153464A2 (en) 2013-03-20 2014-09-25 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
MX2015014249A (es) 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
CN105764511B (zh) 2013-10-04 2019-01-11 艾普托斯生物科学公司 用于治疗癌症的组合物和方法
AU2017370731B2 (en) 2016-12-08 2022-06-02 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
KR20200096914A (ko) 2017-10-30 2020-08-14 압토스 바이오사이언시스 인코포레이티드 암 치료용 아릴 이미다졸
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
WO2022249192A1 (en) * 2021-05-27 2022-12-01 Ramot At Tel-Aviv University Ltd. Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
WO1995003297A1 (en) * 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
CA2224563A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
EP0906099A4 (en) 1996-04-03 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
EP0906307B1 (en) 1996-06-10 2005-04-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
AU724541B2 (en) 1996-06-21 2000-09-21 Allergan, Inc. Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
RU2239429C2 (ru) 1996-10-15 2004-11-10 Джи. Ди. Сирл Энд Ко. Способ применения ингибиторов циклооксигеназы-2 для лечения и профилактики неоплазии
WO1998018788A1 (en) 1996-10-30 1998-05-07 Schering Corporation Piperazino derivatives as neurokinin antagonists
AU9648098A (en) 1997-10-27 1999-05-17 Takeda Chemical Industries Ltd. Adenosine a3 receptor antagonists
EP1031572A4 (en) 1997-11-14 2001-09-19 Sankyo Co PYRIDYLPYRROL DERIVATIVES
WO2000006124A2 (en) 1998-07-30 2000-02-10 Point Biomedical Corporation A novel excipient for the lyophilization of aqueous suspensions of microparticles

Also Published As

Publication number Publication date
BR0114023A (pt) 2004-02-03
PT1318992E (pt) 2005-11-30
DE60112312D1 (de) 2005-09-01
MXPA03002449A (es) 2003-06-19
NO20031270D0 (no) 2003-03-19
US20040038964A1 (en) 2004-02-26
WO2002024680A1 (en) 2002-03-28
KR20030030027A (ko) 2003-04-16
US20070135433A1 (en) 2007-06-14
AU2001287901A1 (en) 2002-04-02
JP2004509882A (ja) 2004-04-02
DK1318992T3 (da) 2005-11-21
IL154949A0 (en) 2003-10-31
CN1471523A (zh) 2004-01-28
ATE300529T1 (de) 2005-08-15
DE60112312T2 (de) 2005-12-29
PL361397A1 (pl) 2004-10-04
EP1318992B1 (en) 2005-07-27
CZ2003793A3 (cs) 2004-04-14
US7199137B2 (en) 2007-04-03
EP1318992A1 (en) 2003-06-18
CY1105251T1 (el) 2010-03-03
HUP0301181A2 (en) 2007-02-28
ES2242767T3 (es) 2005-11-16
CA2423154A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
DK1318992T3 (da) Imidazolderivater som Raf-kinaseinhibitorer
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
DE50310516D1 (de) Fredericamycin-derivate
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20052512L (no) Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
NO20091618L (no) Bicykliske triazoler som proteinkinasemodulatorer
WO2003080582A3 (de) Fredericamycin-derivate
DE60319158D1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
SG153851A1 (en) N-(1-(1-benzyl -4-phenyl-1h-imidazol-2-yl)-2,2-dymethylpropyl)benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer
ATE484508T1 (de) Furylverbindungen
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
DK1682553T3 (da) Thienopyrazoler
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
GB0121494D0 (en) Compounds
BRPI0415390A (pt) compostos de pirazinona substituìda para o tratamento da inflamação
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application